Treatment Outcomes of Retroperitoneal Sarcoma

Active, not recruiting

• Conditions: Retroperitoneal Sarcoma

• Registration Number: NCT06612671
• Lead Sponsor: Taichung Veterans General Hospital

Brief Summary

Investigators tried condult a retrospective study to analysis the prognostic factors and oncological outcome analysis of Retroperitoneal Sarcoma treated in our high volume medical center.

Detailed Description

Retroperitoneal Sarcoma (RPS) which is a rare disease which incidence is 1.79/100,000. The treatment is difficult to due to it anatomy position which often invade to multiple organs and cause the complete surgical resection to be very complex and difficult. It was known to sacrifice one side kidney will improve the resection rate. To this days, successful surgical resection was still the gold standard that provide most benefit in overall survival. To reach that goal, pre-operative radiotherapy was applied to RPS which intended to achieve similar effect in rectal cancer for the down staging effect and improved the respectability but with limited benefit. Herein, investigators conducted this study to find the best way to achieve successful surgical resection and prognostic factor analysis.

Study Timeline

• Study First Submitted: 2023-09-09
• Study Start: 2023-10-01
• Primary Completion: 2024-07-01
• Status Verified: 2024-09
• Study First Submitted QC: 2024-09-22
• Last Update Submitted: 2024-09-22
• Study First Posted: 2024-09-25
• Last Update Posted: 2024-09-25
• Study Completion: 2025-09-30

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

• the patient who have retroperitoneal maliganacy and receive complete tumor excision in our hospital

Exclusion Criteria

• the patient did not receive complete tumor excision in our hospital
• the pathological report yielded not malignancy tumor

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall survival	The proportion of patients still alive at 1 year, 3 years, and 5 years after treatment.	After treatment, patients will undergo long-term follow-up to record their survival status.

Secondary Outcome Measures

Name	Time	Method
Progression free survival	The rates of local recurrence, regional recurrence, or distant metastasis at 1 year, 3 years, and 5 years after treatment.	Progression defined as local, regional, or distant metastasis

Trial Locations

Locations (1)

Taichung Veterans General Hospital; 🇨🇳 Taichung, Taiwan